Epidemiology of influenza over a ten-year period in Belgium: overview of the historical and current evidence.
Epidemiology
Flu
Hospitalisation
Influenza
Vaccination
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
05
06
2023
accepted:
08
11
2023
medline:
23
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Generally influenza, a contagious respiratory disease, leads to mild illness, but can present as a severe illness with significant complications for some. It entails significant health challenges and an economic burden. Annual vaccination is considered the most effective preventive measure against influenza, especially in high-risk groups. Epidemiological, demographic and vaccination data of influenza from 2009-to-2019 is collected from Sciensano, the Belgian Institute for Health. Sciensano monitors influenza virus through two surveillances: the Influenza-Like Illness (ILI) surveillance in primary care and the Severe Acute Respiratory Infections (SARI) surveillance in hospital settings. 49.6% [± 8.5] of all ILI-samples tested positive in this period. Influenza A was the dominant circulating type, accounting for 73.7% [± 27.5] of positive samples, while influenza B accounted for 24.3% [± 26.7]. For SARI-surveillance, the average rate of samples tested positive was 36.3% [± 9.3]. Influenza A was responsible for respectively 77.7% [± 23.8] of positive samples and influenza B for 22.2% [± 23.7]. Since 2010, epidemics typically lasted about 9.3 weeks [± 2.7]. From 2012 to 2019 the average vaccine effectiveness was 34.9% [± 15.3]. Influenza is quickly considered a trivial disease, but can have substantial repercussions. It remains difficult to identify the level of treat of influenza due to antigenic evolution. Measures to prevent, control and treat are needed. Vaccines that provide broader and more durable protection that can be produced more rapidly could be a potential solution.
Sections du résumé
BACKGROUND
BACKGROUND
Generally influenza, a contagious respiratory disease, leads to mild illness, but can present as a severe illness with significant complications for some. It entails significant health challenges and an economic burden. Annual vaccination is considered the most effective preventive measure against influenza, especially in high-risk groups.
METHOD
METHODS
Epidemiological, demographic and vaccination data of influenza from 2009-to-2019 is collected from Sciensano, the Belgian Institute for Health. Sciensano monitors influenza virus through two surveillances: the Influenza-Like Illness (ILI) surveillance in primary care and the Severe Acute Respiratory Infections (SARI) surveillance in hospital settings.
RESULTS
RESULTS
49.6% [± 8.5] of all ILI-samples tested positive in this period. Influenza A was the dominant circulating type, accounting for 73.7% [± 27.5] of positive samples, while influenza B accounted for 24.3% [± 26.7]. For SARI-surveillance, the average rate of samples tested positive was 36.3% [± 9.3]. Influenza A was responsible for respectively 77.7% [± 23.8] of positive samples and influenza B for 22.2% [± 23.7]. Since 2010, epidemics typically lasted about 9.3 weeks [± 2.7]. From 2012 to 2019 the average vaccine effectiveness was 34.9% [± 15.3].
CONCLUSION
CONCLUSIONS
Influenza is quickly considered a trivial disease, but can have substantial repercussions. It remains difficult to identify the level of treat of influenza due to antigenic evolution. Measures to prevent, control and treat are needed. Vaccines that provide broader and more durable protection that can be produced more rapidly could be a potential solution.
Identifiants
pubmed: 37990263
doi: 10.1186/s12985-023-02238-1
pii: 10.1186/s12985-023-02238-1
pmc: PMC10664657
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
271Informations de copyright
© 2023. The Author(s).
Références
Curr Opin Infect Dis. 2017 Apr;30(2):201-207
pubmed: 27984245
Viruses. 2019 Mar 07;11(3):
pubmed: 30866478
J Prev Med Hyg. 2016;57(1):E28-33
pubmed: 27346937
Expert Rev Vaccines. 2018 Jun;17(6):495-502
pubmed: 29883218
Health Aff (Millwood). 2016 Nov 1;35(11):2124-2132
pubmed: 27733424
Vaccine. 2019 May 27;37(24):3179-3189
pubmed: 31047677
J Theor Biol. 2008 Jul 7;253(1):118-30
pubmed: 18402981
Vaccine. 2005 Jul 8;23 Suppl 1:S1-9
pubmed: 15908058
Emerg Infect Dis. 2019 Feb;25(2):
pubmed: 30666948
Drugs. 2004;64(18):2031-46
pubmed: 15341496
Influenza Other Respir Viruses. 2019 Jan;13(1):18-27
pubmed: 30137663
Pediatrics. 2021 Oct;148(4):
pubmed: 34470815
J Microbiol Immunol Infect. 2021 Oct;54(5):865-875
pubmed: 34020891
Vaccine. 1995 Oct;13(14):1263-76
pubmed: 8585280
Vaccine. 2007 Sep 28;25(39-40):6852-62
pubmed: 17719149
Methods Mol Biol. 2018;1836:1-21
pubmed: 30151566
PLoS One. 2019 Sep 12;14(9):e0222381
pubmed: 31513690